Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15 G/L, treated with front-line azacitidine versus conventional care regimens within a phas...

Full description

Bibliographic Details
Main Authors: Lisa Pleyer, Hartmut Döhner, Hervé Dombret, John F. Seymour, Andre C. Schuh, CL Beach, Arlene S. Swern, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstöcker, Eva M. Autzinger, Alois Lang, Klaus Geissler, Daniela Voskova, Wolfgang R. Sperr, Sabine Hojas, Inga M. Rogulj, Johannes Andel, Richard Greil
Format: Article
Language:English
Published: MDPI AG 2017-02-01
Series:International Journal of Molecular Sciences
Subjects:
acute myeloid leukaemia (AML)
AZA-AML-001 trial
Austrian Azacitidine Registry (AAR)
real-world data
azacitidine
Online Access:http://www.mdpi.com/1422-0067/18/2/415

Similar Items

Similar Items